The role of epoetin beta in the treatment of anaemia in patients with gynaecological malignancies

Anticancer Research

Volumn 27, Issue 1 B, 2007, Pages 513-522

  Cornes, Paul ^a   Boiangiu, I ^a  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Anaemia; Cervical neoplasms; Epoetin beta; Ovarian neoplasms; Review; Supportive care

Indexed keywords

CISPLATIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; FEMALE; FLU LIKE SYNDROME; GYNECOLOGIC CANCER; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INJECTION SITE PAIN; MALAISE; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPLENOMEGALY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UTERINE CERVIX CANCER; VOMITING;

ANEMIA; COMBINED MODALITY THERAPY; DRUG THERAPY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 33847700189     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M and Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293-2306, 2004.
2. Nowrousian MR: Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15(Suppl 1): S19-S28, 1998.
3. Spivak JL: The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 5: 543-555, 2005.
4. Campos S: The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol 29(3 Suppl 8): 7-12, 2002.
5. Wood PA and Hrushesky WJ: Cisplatin-associated anemia: an erythropoietin deficiency syndrome: J Clin Invest 95: 1650-1659, 1995.
6. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL and Portenoy RK: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(Suppl 2): 4-12, 1997.
7. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK and Vogelzang NJ: Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5: 353-360, 2000.
8. Caro JJ, Salas M, Ward A and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer; a systematic, quantitative review. Cancer 91: 2214-2221, 2001.
9. Bush RS, Jenkin RDT, Allt WEC, Beale FA, Bean H, Dembo AJ and Pringle JF: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37(Suppl III): 302-6, 1978.
10. Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, Portelance L, Crook J and Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-1536, 1999.
11. Höckel M, Schlenger K, Höckel S and Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59: 4525-4528, 1999.
12. Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W, Rath FW, Molls M and Dunst J: Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys 50: 865-872, 2001.
13. Obermair A, Cheuk R, Horwood K, Neudorfer M, Janda M, Giannis G, Nicklin JL, Perrin LC and Crandon AJ: Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. Int J Gynecol Cancer 13: 633-639, 2003.
14. Evans JC and Bergsjø P: The influence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology 84: 709-717, 1965.
15. Bush RS: The significance of anemia in clinical radiation therapy: Int J Radiat Oncol Biol Phys 12: 2047-2050, 1986.
16. Münstedt K, Kovacic M, Zygmunt M and von Georgi R: Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 23: 837-843, 2003.
17. Thomas GM: Raising hemoglobin: an opportunity for increasing survival? Oncology 63(Suppl 2): 19-28, 2002.
18. Vaupel P, Thews O and Hoeckel M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18: 243-259, 2001.
19. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H and Haensgen G: Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56: 778-787, 2003.
20. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB and Glaspy JA: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95: 888-895, 2002.
21. Thomas G: The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 28(Suppl 8): 60-65, 2001.
22. Kapp KS, Poschauko J, Geyer E, Berghold A, Oechs AC, Petru E, Lahousen M and Kapp DS: Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 54: 58-66, 2002.
23. Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DB, Skacel P and Barbara JA: Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 319: 16-19, 1999.
24. Jensen PD, Jensen FT, Christensen T, Nielsen JL and Ellegaard J: Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 101: 91-96, 2003.
25. Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB and Potish RA: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29: 1079-1084, 1994.
26. Blohmer J-U, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R, Dressler P, Kentenich H and Kohls A: Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 15(Suppl 3): iii128 (Abstract 477PD), 2004.
27. Strauss H, Haensgen G, Dunst J, Hayward C and Koelbl H: Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy. Proc Am Soc Clin Oncol 23(Suppl 16, part I of II): 484s (Abstract 5121), 2005.
28. Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P; EPO-INT-45 Study Group: Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 94: 947-954, 2006.
29. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D; for the Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494, 2002.
30. Boogaerts M, Coiffier B, Kainz C and the Epoetin β QOL Working Group: Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88: 988-995, 2003.
31. Cazzola M, Beguin Y, Kloczko J, Spicka I and Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122: 386-393, 2003.
32. Glimelius B, Linné T, Hoffman K, Larsson L, Svensson JH, Näsman P, Svensson B and Helmers C: Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434-440, 1998.
33. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N and Zwierzina H: Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255-260, 1998.
34. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Hoeven JJ, Reed NS, Fairlamb DJ, Chan SY, Godfrey KA, Kristensen GB, van Tinteren H and Ehmer B: Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Medical Oncol 15: 174-182, 1998.
35. Bogdanos J, Karamanolakis D, Milathianakis K, Repousis P, Chloraki-Bobota A, Majed H, Pagalou-Thoua E, Tsintavis A and Koutsilieris M: Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Res 24: 1957-1962, 2004.
36. Marangolo M, Malamos N, Pedrini JL, Rotarski M, Láng I, Beato C, Colomer R and Ukarma L: Epoetin beta in patients with metastatic breast cancer receiving chemotherapy: Results from the Breast Cancer - Anemia and the Value of 61. Erythropoietin (BRAVE) study. Proc Am Soc Clin Oncol 23(Suppl 16, part I of II): 764s (Abstract 8141), 2005.
37. Ordóñez A, González-Barón M, Isla D, Sánchez A, Arrivi A and Manzano JL: Epoetin beta treatment to prevent anemia in solid tumor patients receiving platinum-based chemotherapy. Proc Am Soc Clin Oncol 23(Suppl 16, part I of II): 785s (Abstract 8230), 2005.
38. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Österborg A, Repetto L and Soubeyran P: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201-2216, 2004.
39. Cremieux PY, Finkelstein SN, Berndt ER, Crawford J and Slavin MB: Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16(5 Pt 1): 459-472, 1999.
40. Ozsahin M, Azria D, Beer K, Mirimanoff RO and Zouhair A: External radiotherapy and anaemia treatment: state of the art. Swiss Med Wkly 135: 4-10, 2005.
41. Antonadou D, Cardamakis E, Puglisi M, Malamos N and Throuvalas N: Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomised phase III study. Eur J Cancer 37(Suppl 6): S144 (A530), 2001.
42. Reed N, Chan S, Hayward C, Burger H-U and ten Bokkel Huinink W: Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy. Proc Am Soc Clin Oncol 23(Suppl 16, part I of II): 479 (Abstract 5102), 2005.
43. Aapro M, Dunst J, Morère J-F, Nowrousian MR, Huber M and Burger H-U: Effect of epoetin beta on tumor progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 15(Suppl 3): Abstract 841P, 2004.
44. Marinaccio M, Mele E, Poma S, Cantinieri C, Cocca M and Latiano T: Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer. Proc Am Soc Clin Oncol 22(Suppl 14): 480 (Abstract 5132), 2004
45. NeoRecormon® product information, Roche Pharmaceuticals, Basel, Switzerland, 17 November 2005. Available at: http://www.emea.eu.int/humandocs/ Humans/EPAR/neorecormon/neorecormon.htm.
46. Spaëth D, Oudard S, Ferrero J-M, Rixe O, Deplanque G, Fiorentini P and Berougnoux L: Once weekly epoetin beta 30000 IU: an effective and well tolerated therapy for anaemia in chemotherapy-treated patients with solid or lymphoid malignancies. NAUTICA study investigators. Ann Oncol 17 (Suppl 9): ix294-ix295 (abstract 1020p), 2006.
47. Coiffier B, Boogaerts M, Aapro M, Huber M and Burger H-U: Thromboembolic events in patients with cancer treated with epoetin beta: a meta-analysis of controlled clinical trials. Ann Oncol 15: iii221 (Abstract 840P), 2004.
48. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C and Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489-498, 2005.
49. Wun T, Law L, Harvey D, Sieracki B, Scudder SA and Ryu JK: Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation and erythropoietin. Cancer 98: 1514-1520, 2003.
50. Veys N, Dhondt A and Lameire N: Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 49: 41-44, 1998.
51. Oudard S, Berthoux F, Fiorentini P and Montestruc F: Results of a cross-over study on injection-site pain comparing subcutaneous epoetin beta and darbepoetin alfa in healthy volunteers. Eur J Cancer 3(Suppl): 372(Abstract 1288), 2005.
52. Henke M, Laszig R, Rübe C, Schäfer U, Haase K-D. Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
53. Glaspy J and Dunst J: Can erythropoietin therapy improve survival? Oncology 67(Suppl 1): 5-11, 2004.
54. Vaupel P, Dunst J, Engert A, Fandrey J, Feyer P, Freund M and Jelkmann W: Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 28: 216-221, 2005.
55. Leyland-Jones B on behalf of the BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet 4: 459-460, 2003.
56. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X and Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972, 2005.
57. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C and Engert A: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708-714, 2006.
58. Boogaerts M, Oberhoff C, ten Bokkel Huinink W, Nowrousian MR, Hayward CRW and Burger HU: Epoetin beta (NeoRecormon®) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 26(1B): 479-484, 2006.
59. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: Cancer and treatment-related anaemia v2. 205. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf.
60. Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A and Littlewood TJ: Erythropoietin: a paradigm for the development of practice guidelines. Hematology Am Soc Hematol Educ Program 10-30, 2001.
61. Nag S, Chao C, Erickson B, Fowler J, Gupta N, Martinez A and Thomadsen B; American Brachytherapy Society: The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 52: 33-48, 2002. Erratum in: Int J Radiat Oncol Biol Phys 52: 1157, 2002.
62. Quirt I, Bramwell V, Charette M, Oliver T and the systemic treatment disease site group: The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. Practice guideline report #12-1. Available from: http://www.cancercare.on.ca/pdf/pebc12- 1f.pdf (accessed 17 Sept 2005).
63. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP and Gordon MS; American Society of clinical oncology, American Society of Hematology: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002.
64. Pecorelli S; "Consensus Meeting - Use of Erythropoietin in Gynecologic Tumors", held in Rome, Italy, March 5, 1999: The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia. Semin Oncol 29(3 Suppl 8): 13-15, 2002.
65. Marchal C, Spaeth D, Casadevall N, Daouphars M, Marec-Berard P, Fabre N and Haugh M: Recommandations pour la pratique clinique: Standards, options et recommandations 2003 pour l'utilisation de l'érythropoïétine recombinante (époetine alfa et bêta, darbepoetine alfa, EPO) dans la prise en charge de l'anémie en cancérologie pour les patients traités par radiothérapie, mise à jour. Cancer/Radiothérapie 8: 197-206, 2004.